On Thursday, UBS initiated coverage on CG Oncology (NASDAQ:CGON), assigning the stock a Buy rating with a price target of $60.00. The coverage comes with a positive outlook on the company's lead program, cretostimogene (creto), which is being developed for non-muscle invasive bladder cancer (NMIBC).
CG Oncology's creto is at the forefront of the firm's optimism, with UBS projecting a peak sales opportunity of $1.9 billion, surpassing the consensus estimate of $1.6 billion. The firm considers the current market undervaluation of creto to be based on recent debates over its efficacy compared to Johnson & Johnson's TAR-200.
UBS highlighted creto's potential advantages over TAR-200, including superior durability, a clean safety profile, and a simpler administration procedure. The treatment also offers a less intensive regimen and can be easily integrated into existing urology practices. These attributes are expected to help creto capture a significant portion of the market in BCG-unresponsive high-risk NMIBC.
Key opinion leaders (KOLs) have suggested that creto could take substantial market share in this segment. UBS anticipates several near-term catalysts for CG Oncology, including a clinical update on creto in BCG-unresponsive high-risk NMIBC in the second half of 2024 and regulatory updates expected in 2025.
In other recent news, CG Oncology has been the focus of several analyst firms following the release of clinical data. Goldman Sachs reiterated its Buy rating on CG Oncology, emphasizing the potential of its drug, cretostimogene, in treating non-muscle invasive bladder cancer. The firm maintains a $52 price target, noting the drug's safety, efficacy, and ease of administration. H.C. Wainwright also maintained its Buy rating and a $75 price target, highlighting cretostimogene's safety profile, with no treatment-related adverse events and discontinuations.
Roth/MKM issued a Buy rating with a $65 target, citing cretostimogene's potential to capture market share due to its tolerability. The firm also underscored the drug's efficacy, which is promising for the treatment of both high-risk and intermediate-risk non-muscle invasive bladder cancer. These recent developments underscore the ongoing interest in CG Oncology's work in the oncology space, especially in light of competing treatments.
The final analysis from CG Oncology's BOND-003 trial is expected by the end of 2024, with results likely to be presented at the Society of Urologic Oncology meeting. This timeline coincides with the company's plans for a Biologics License Application submission in 2025.
InvestingPro Insights
To complement UBS's positive outlook on CG Oncology (NASDAQ:CGON), recent data from InvestingPro provides additional context for investors. The company's market capitalization stands at $2.39 billion, reflecting the market's current valuation of its potential in the oncology space.
InvestingPro Tips highlight that analysts anticipate sales growth for CG Oncology in the current year, aligning with UBS's optimistic projections for the company's lead program, cretostimogene. This expectation is further supported by the impressive revenue growth of 172.68% reported in Q1 2024, indicating strong momentum in the company's commercial development.
However, it's important to note that CG Oncology is not currently profitable, with a negative P/E ratio of -33.07 for the last twelve months as of Q1 2024. This is not unusual for biotech companies in the development stage, especially those with promising pipelines like creto. The company's ability to hold more cash than debt on its balance sheet suggests financial stability to support ongoing research and development efforts.
For investors seeking a deeper understanding of CG Oncology's financial health and growth prospects, InvestingPro offers 7 additional tips, providing a more comprehensive analysis to inform investment decisions in this dynamic biotech company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.